The latest price target for Terns Pharma (NASDAQ:TERN) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $7.50 expecting TERN to rise to within 12 months (a possible 16.02% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Terns Pharma (NASDAQ:TERN) was provided by HC Wainwright & Co., and Terns Pharma maintained their neutral rating.

There is no last upgrade for Terns Pharma

The last downgrade for Terns Pharmaceuticals Inc happened on March 23, 2022 when JP Morgan changed their price target from $19 to $6 for Terns Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Terns Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Terns Pharma was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Terns Pharma (TERN) rating was a maintained with a price target of $5.50 to $7.50. The current price Terns Pharma (TERN) is trading at is $6.46, which is within the analyst’s predicted range.